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Acanthamoeba spp. and Balamuthia mandrillaris are causative agents of 23 
granulomatous amoebic encephalitis (GAE), while Naegleria fowleri causes primary amoebic 24 
meningoencephalitis (PAM). PAM is an acute infection lasting few days, while GAE is a 25 
chronic to subacute infection that can last up to several months. Here, we present a literature 26 
review of 86 case reports from 1968 to 2016 in order to explore affinity of these amoebae 27 
towards particular sites of the brain, diagnostic modalities, treatment options and the disease 28 
outcome in a comparative manner.  29 
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Acanthamoeba spp., Balamuthia mandrillaris and Naegleria fowleri are pathogenic 35 
free-living amoebae (1). They are well-known to produce fatal central nervous system 36 
infections, however pathogenic Acanthamoeba spp., can also produce blinding keratitis that is 37 
often associated with the inappropriate use of contact lenses. All three genera are known as 38 
amphizoic amoebae, due to their ability to exist as parasitic organisms as well as inhabit 39 
natural environment as free-living. In nature, Acanthamoeba seems to be most ubiquitous that 40 
can inhabit a variety of environments and has been isolated from soil, water, and air, whereas 41 
B. mandrillaris is rather selective, living in the soil and has been rarely isolated from water 42 
(1-3). Naegleria fowleri, being thermophilic protist, prefers warm water such as hot spring in 43 
temperate zone and lakes in the tropics (4, 5). Acanthamoeba spp. and B. mandrillaris are 44 
known to have two stages in their life cycle, including a vegetative trophozoite stage and a 45 
dormant cyst form, while N. fowleri exhibits an additional transient flagellate form in 46 
addition to the trophozoite and cyst form (1-6). These forms are interchangeable depending 47 
on the environmental conditions. Among the various forms, the trophozoite form is often the 48 
infectious one. These amoebae cause two distinct clinical entities including, granulomatous 49 
amoebic encephalitis (GAE) caused by pathogenic Acanthamoeba spp., and B. mandrillaris, 50 
and primary amoebic meningoencephalitis (PAM) caused by N. fowleri. Both GAE and PAM 51 
are distinguished by their aetiology, risk factors, duration of illness, clinical features, 52 
laboratory and imaging findings (6). N. fowleri is the only known pathogenic species that 53 
causes human disease in the genus Naegleria that consists of over 40 species, while B. 54 
mandrillaris is the only species isolated in the genus Balamuthia. Genus Acanthamoeba is 55 
classified into 20 genotypes (T1 – T20) (1-3, 7, 8). These amoebae and associated infections 56 
have garnered increasing scientific/medical interests in recent years due to poor prognosis, 57 
i.e., less than 5% patients survive if early intervention is not initiated (1, 6). In addition to 58 
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poor prognosis, cases of amoebic meningoencephalitis are often under-reported and under-59 
recognized globally due to lack of awareness, absence of availability of diagnostic measures, 60 
lack of access to wide distribution of knowledge on public health issues especially in 61 
developing countries and similarity of symptomatology with other common causes of central 62 
nervous system (CNS) infections such as viral and bacterial meningitis. In addition, a 63 
complete understanding of the pathogenesis and pathophysiology of CNS infection due to 64 
aforementioned free-living amoebae is incompletely understood. For example, PAM is an 65 
acute infection lasting only a few days, while GAE is a chronic to subacute infection lasting 66 
up to several months. Given the nasal route of entry, N. fowleri is likely to have an intimate 67 
correlation with the frontal lobe, due to anatomical proximity of olfactory bulb to the frontal 68 
lobe, of which the olfactory bulb is terminal to the olfactory neuroepithelium of the nasal 69 
passage, traversing through the cribriform plate to the brain (1, 6). Although intranasal route 70 
is the mode of infection, current administration of drugs (such as amphotericin B) against 71 
PAM is via the intravenous route that causes significant toxicity to other tissues and require 72 
high dosage to reach the site of infection at sufficient concentration to kill the parasite. In 73 
contrast, pathogenic Acanthamoeba and B. mandrillaris spread haematogenously and 74 
possibly distribute in the frontal lobe, the temporal lobe and the parietal lobe, likely through 75 
the middle cerebral artery, as these cortices are among the main regions for middle cerebral 76 
artery supply (9). By studying the available reported cases of CNS infection due to free-living 77 
amoebae comparatively, the aim of the present study is to determine the principle sites of 78 
infection within the brain, diagnostic methods employed, pre-mortem and post-mortem, and 79 
available treatment regimens with a examples of successful prognosis, with an eye to increase 80 














Case studies of amoebic meningo-encephalitis: Predilection sites in the brain  84 
In this review, we examined cases presenting brain infections due to free-living 85 
amoebae, Acanthamoeba spp., B. mandrillaris and Naegleria fowleri. In total, we examined 86 
86 case reports that are available on Pubmed from 1968 to 2016, in order to explore the 87 
affinity of these three amoebae towards particular sites of the brain. For GAE due to 88 
pathogenic Acanthamoeba, a total of 46 cases were reviewed that were reported in 35 89 
publications; GAE due to B. mandrillaris, a total of 29 cases were reviewed from 16 90 
publications, while for PAM due to N. fowleri, 11 cases were reviewed from 10 publications. 91 
The majority of cases were reported in the America (up to 90%). PAM due to N. fowleri was 92 
reported in immunocompetent individuals, while GAE was reported in both 93 
immunosuppressed (mostly Acanthamoeba cases) as well as immunocompetent individuals 94 
(mostly B. mandrillaris cases). The cases were stratified based on the year of the report, 95 
patient’s age and gender, place of origin, chief complaints, relevant positive and negative 96 
findings, laboratory findings (cerebrospinal fluid, blood profiles, serology and cultures), 97 
diagnosis, neuroimaging, definitive treatments and disease outcome. In earlier literature dated 98 
from 1960-1970, B. mandrillaris was recognized as Leptomyxid genus when taxonomical 99 
categorization was not clear (10), however these cases have been included in this review as B. 100 
mandrillaris infections. Cases with imaging studies included MRI imaging (27 cases), CT 101 
scans (24 cases), and a combination of CT and MRI (16 cases). As it is a study on preferential 102 
sites, first imaging studies on first admission was selected for analyses unless stated 103 
otherwise. Moreover, if two imaging modalities were done at once during first admission, 104 
MRI is considered superior to CT in terms of demonstrating focal lesions that are evolving 105 
over time. Therefore, we prioritize MRI images and descriptions over CT images and 106 
descriptions (78). However, MRI availability is limited in some parts of the world, hence CT 107 
images were used as standard imaging in such instances.  108 
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Neuroimaging of GAE typically showed multiple well-defined focal ring-enhancing 109 
space occupying lesions with perilesional edema and leptomeningeal enhancement if 110 
meninges are involved (11). PAM in neuroimaging has single focus of infection with diffuse 111 
cerebral edema, signs of increased intracranial pressure (midline shift and effacement of 112 
ventricles and cisterns) and basilar meningeal enhancement (11). For GAE due to pathogenic 113 
Acanthamoeba spp., 12 cases (26.1%) were reported to have lesions in the frontal lobe, 11 114 
cases (23.9%) in the parietal lobe, 12 cases (26.1%) reported lesions in the temporal lobe, 9 115 
cases (19.6%) in the occipital lobe respectively. While for sites beyond cerebral cortices, 116 
cortico-medullary junction and cerebellum made up most of the cases (17.4% and 8.7% 117 
respectively). In 2 cases (4.3%), the thalamus was also affected. The cerebrospinal fluid (CSF) 118 
drainage system is favored in 5 cases (10.9%) (with hydrocephalus), while generalized edema 119 
was found in 1 case (2.2%) (Fig. 1; supplementary Table 1). There are possible false negative 120 
findings in 2 cases (4.3%) where normal findings on early imaging were observed. Other sites 121 
made up 8 cases (17.4%) of GAE due to Acanthamoeba. Overall, frontal lobe, parietal lobe, 122 
temporal lobe and occipital lobe (constituted 56% of total cases reviewed in this study) were 123 
affected in most cases of GAE due to Acanthamoeba.     124 
For GAE due to B. mandrillaris, 12 cases (41.4%) reported the involvement of the 125 
frontal lobe, 10 cases (21.7%) reported lesions in the parietal lobes, 15 cases (51.7%) 126 
reported lesions in the temporal lobe, and 9 cases (31%) reported lesions in the occipital lobe, 127 
respectively. The sites beyond the cerebral cortices included the involvement of cortico-128 
medullary junction, thalamus, basal ganglia, and the cerebellum (Fig. 2; supplementary Table 129 
2). Notably, one case was manifested as an aneurysm, while two cases affected the CSF 130 
drainage. In one case, co-infection of advanced HIV infection, Acanthamoeba and B. 131 
mandrillaris with cerebral toxoplasmosis was observed. Overall, the frontal lobe, parietal 132 
lobe, temporal lobe and occipital lobe (constituted 54% of total cases reviewed in this study) 133 
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were affected in most cases of GAE due to B. mandrillaris, which appears consistent with 134 
GAE due to Acanthamoeba.   135 
For PAM due to N. fowleri, it was observed that the parasite favours the frontal lobe, 136 
followed by the parietal lobe. Among the reported cases of PAM due to N. fowleri, 36% cases 137 
reported the involvement of the frontal lobe (Fig. 3; supplementary Table 3). The sites 138 
beyond the cerebral cortices included cortico-medullary junction, while the CSF drainage 139 
system was targeted in 27% of cases. Three cases (27%) showed signs of hydrocephalus. 140 
Notably, one case of PAM showed normal findings on neuroimaging. In comparison to GAE 141 
due to Acanthamoeba spp., and B. mandrillaris, the frontal lobe constituted 37% of total 142 
cases reviewed in this study) were affected in most cases of PAM due to N. fowleri.  143 
 144 
Case studies of amoebic meningo-encephalitis: Diagnosis  145 
Among GAE due to Acanthamoeba spp. cases, 34.5% cases were diagnosed at post-146 
mortem and 65.5% cases were identified pre-mortem (Table 1). Among the post-mortem 147 
cases, microscopy was used successfully in 10.9% of cases, immunofluorescence assays (IFA) 148 
were used effectively in 18.2% of cases, and polymerase chain reaction (PCR) was used 149 
positively in 5.4% of cases. In pre-mortem cases, CSF observation of amoebae were made in 150 
38.1% of cases [using microscopy (14.5% cases), culture of parasites (20% cases), and PCR 151 
(3.6%)] and brain biopsies were made in 30.41% of cases [using microscopy (15.21%), 152 
culture (4.34%), PCR (4.34%), and IFA (6.52%)]. Collectively, in GAE due to 153 
Acanthamoeba spp., observation of parasites in CSF samples using culture and microscopy 154 
was the most widely used diagnostic method reported pre-mortem.     155 
For GAE due to B. mandrillaris cases, 31% cases were diagnosed at the post-mortem 156 
stage and 68.9% cases were identified pre-mortem (Table 1). Among the post-mortem cases, 157 
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microscopy was used successfully in 10.34% of cases, and IFA was used effectively in 20.68% 158 
of cases reported. In pre-mortem cases, CSF observation of amoebae was made in 3.44% of 159 
cases [using PCR], and brain biopsies were made in 44.81% of cases [using microscopy 160 
(20.68%), PCR (10.34%), and IFA (13.79%)]. Overall, among GAE due to B. mandrillaris 161 
cases, observation of parasites in brain biopsies using microscopy and IFA was the most 162 
widely used diagnosis pre-mortem.  163 
Among PAM due to N. fowleri cases, 63.7% cases were diagnosed at post-mortem 164 
and 36.3% cases were identified pre-mortem (Table 1). Among post-mortem cases, 165 
microscopy was used successfully in 36.4% of cases, IFA was used effectively in 18.2% of 166 
cases, and PCR was used positively in 9.1% of cases reported. In pre-mortem cases, CSF 167 
observation of amoebae was made in 36.4% of cases [using microscopy (18.2%), and culture 168 
(18.2)]. Overall, among PAM due to N. fowleri cases, observation of parasites in CSF 169 
samples using microscopy and IFA was the most widely used diagnosis pre-mortem.  170 
 171 
Case studies of amoebic meningo-encephalitis: Treatment  172 
With all the treated case studies compiled, despite establishment of clinical guidelines 173 
on amoebic meningoencephalitis, the physicians had been liberal with combinations of 174 
several classes of drugs with different mechanisms of action and individualized according to 175 
age, gender, availability of chemotherapy and underlying medical conditions which may 176 
affect metabolism of drugs, therefore we examined accordingly by classes of 177 
chemotherapeutic agents instead of combinations of the agents. The percentage was 178 
determined by cases of GAE (Acanthamoeba and Balamuthia) and PAM separately. In 179 
determination of outcomes in diseases, survival cases were deemed successful while the cases 180 
that result in death which include brain death was considered as poor outcome.  181 
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When reviewing reported cases of amoebic meningoencephalitis, it is clear that there 182 
is no effective drug against GAE or PAM and as a result, the majority of cases resulted in 183 
death. Various types of drugs and their combinations have been tested but the prognosis 184 
remained poor. For example, in the GAE due to Acanthamoeba spp., cases reviewed here, the 185 
most commonly used drugs include the Azole compounds, Sulfonamides, Amphotericin B, 186 
Sulfadiazine, Macrolides, Miltefosine, Pentamidine, Flucytosine, and Rifampicin (Table 2). 187 
In contrast, Azole compounds, Sulfadiazine, Petamidine, Miltefosine and Amphotericin B 188 
were most commonly used in GAE cases due to B. mandrillaris. For PAM due to N. fowleri, 189 
the most commonly used drugs included Amphotericin B, Azole compounds, Sulfadiazine, 190 
and Rifampicin (Table 2). Among cases with successful prognosis, there appears to be a 191 
combination of several compounds (Table 3). In some of these cases, a combination of 192 
Amphotericin B, Sulfamethoxazole and Trimethoprim, and Rifampicin was given in the 193 
treatment of GAE due to Acanthamoeba spp. (Table 3). In contrast, combination of 194 
Flucytosine, Fluconazole, Azithromycin, Pentamidine, Sulfadiazine, Azithromycin, and 195 
Miltefosine was given in the majority of GAE cases due to B. mandrillaris (Table 3). For 196 
PAM, in recent years, a combination of Amphotericin B, Fluconazole, Rifampin, 197 
Azithromycin, Dexamethasone, Miltefosine was given (Table 3).  198 
 199 
Challenges and opportunities  200 
Free-living pathogenic amoebae are now well recognized agents of brain infection 201 
leading to GAE and PAM. GAE is a chronic infection that can lasts up to several months, 202 
while PAM is an acute, fulminant infection lasting few days (1, 6). It is intriguing to see the 203 
distinctive difference of chronicity in pathogenicity of these amoebae. For example, 204 
Acanthamoeba and B. mandrillaris likely enter the host via the lower respiratory tract and/or 205 
skin breaks (1, 6). In contrast, N. fowleri enter the host via the nasal route. Recently, another 206 
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route of entry has been included, i.e., via organ transplantations, leading to recipients of 207 
organ donations in acquiring amoebic meningoencephalitis from the donor who was 208 
diagnosed with amoebic meningoencephalitis post-mortem of the same genotype (22-25). 209 
This is important as amoebae are ubiquitous, non-responsive to antibiotics, and organ 210 
recipients are already rendered immunosuppressed, thus any entry of these pathogenic free-211 
living amoebae may lead to devastating consequences. Although risk factors data was not 212 
available for all cases reviewed in this study, there are factors that were observed to dictate 213 
susceptibility of patients to amoebic meningoencephalitis. For GAE due to Acanthamoeba, 214 
immunosuppression appeared to be a factor (1, 6, 26, 27), while B. mandrillaris was shown to 215 
infect immunocompetent individuals, in addition to immunocompromised patients (1,3). 216 
Preceding cutaneous lesions are often liable to GAE caused by both amoebae. Primary 217 
amoebic meningoencephalitis usually occurred in immunocompetent children and young 218 
adults (1, 6, 7). However, all patients had history of activities in proximity to fresh water 219 
sources such as swimming pools, hot springs, recreational activities, religious practices such 220 
as ablution, and healthcare practices such as the use of neti pots. Eliciting a thorough patient 221 
history is absolutely paramount for the accurate diagnosis of PAM and public health 222 
preventive measures such as water treatment should be taken for high risk populations. 223 
Neuroimaging studies revealed the location of lesions in the frontal, parietal and 224 
temporal lobes in most cases of GAE, but the lesions were much more frequent in the frontal 225 
lobe for N. fowleri. Neuroimaging modalities however can have false negative results, 226 
therefore specificity of neuroimaging in diagnosis of amoebic meningoencephalitis is yet to 227 
be evaluated. In the absence of accurate diagnosis and effective treatment, both diseases often 228 
result in death. N. fowleri was found more often in the CSF than the other two amoebae, most 229 
likely due to its motile flagellated form. However, the diagnosis in biopsy may be hindered 230 
by the inoculum size and magnitude of inflammation and necrosis in the tissue section. In 231 
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addition to factors above, morphology of trophozoites in tissue section bears a close 232 
resemblance to macrophages under untrained eyes which are also common in acute 233 
inflammatory response. The other challenge in diagnosis include wide spectrum of 234 
differential diagnosis ranging from brain tumors, multiple sclerosis, lupus encephalitis, 235 
progressive multifocal leukoencephalopathy, stroke, meningitis of other causes (viral, 236 
tuberculous or pyogenic), and cerebral toxoplasmosis (1, 6). A recent case of cerebral 237 
toxoplasmosis complicated by GAE caused by both Acanthamoeba and B. mandrillaris has 238 
highlighted the complex nature of the disease, especially as both amoebae are known to act as 239 
reservoir hosts for many microorganisms (1, 6, 14-16). What is more intriguing is that 240 
Acanthamoeba and B. mandrillaris meningoencephalitis cases present as vascular diseases 241 
(masquerading as cerebral vascular occlusion or aneurysm). This is most likely due to ability 242 
of amoebae to produce endothelial damage resulting in cytokine release, crossing of the 243 
blood-brain barrier, granulomatous inflammation, thromboembolic event, increased vascular 244 
permeability and ultimately necrosis.  245 
For chemotherapeutic strategy, current available delivery routes include intravenous, 246 
oral and intrathecal administration. However, systemic antimicrobial treatment has its 247 
limitations due to its adverse effects and reduced delivery together with delayed diagnosis. 248 
Other concerns include, poor pharmacodynamics and pharmacokinetics profiles of available 249 
drugs, solubility, CNS penetration, drug-drug interactions, patient’s medical conditions, 250 
patient’s tolerance and Acanthamoeba susceptibility to amoebicidal agents (17). In the case 251 
of PAM, Amphotericin B deoxycholate preparation is preferable against N. fowleri infection 252 
compared with its liposomal formulation, albeit it has no effect on Acanthamoeba and B. 253 
mandrillaris (18, 19). More recently, Miltefosine has shown promising results in bio-254 
availability and low drug-drug interactions (18). Of note, the major group of azole and 255 
macrolides are amoebistatic rather than amoebicidal. Additionally, nephrotoxic and 256 
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hepatotoxic effects due to the use of drugs in patients with compromised renal and liver 257 
functions (such as transplant patients) may further complicate the treatment. Potential drug 258 
delivery systems which directly target the inoculation sites of amoebae by circumventing the 259 
needs for optimal blood-brain barrier penetration should be the focus of future studies, thus 260 
increasing the odds of survival in patients with PAM, while minimizing adverse effects and 261 
complications from the diseases. Overall, a complete understanding of the pathogenetic 262 
mechanisms together with the role of immune system and the development of novel 263 
chemotherapeutic approaches in drug delivery (20, 21) is important for the rational 264 
development of anti-amoebic therapy.  265 
 266 
Concluding remarks  267 
Despite advances in clinical presentation, diagnostic methods and treatment 268 
approaches, the mortality associated with CNS infections due amoebae has remained high. 269 
Although neuroimaging findings reveal common areas of lesions, they may not be consistent 270 
and vary depending on the causative agent. A high level of clinician suspicion is important, 271 
especially in refractory cases of meningoencephalitis for rapid diagnosis of the infection, 272 
which is a pre-requisite in the successful treatment. Given that only a few individuals among 273 
all hosts exposed to these amoebae develop infection suggest the possible presence of 274 
underlying predisposing factors. Future research is needed to define genetic, immunological, 275 
pathogenic and environmental factors that contribute to deadly ameobic meningoencephalitis. 276 
Moreover, the ability of pathogenic amoebae to host other microbial pathogens as reservoirs 277 
and act as hyper-parasites has enhanced their capacity as pathogens of increasing importance 278 
to human and animal health.    279 
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Figure 1. The sites of infection of granulomatous amoebic encephalitis due to 502 
Acanthamoeba spp. The majority of cases were within cerebral cortices with frontal lobe and 503 
temporal lobe most affected, followed by parietal and occipital lobe. As for extracortical sites, 504 
cerebellum and cortico-medullary junction are most favoured sites. Furthermore, 505 
hydrocephalus is observed in few cases, which results from blockage of CSF drainage. Other 506 
sites affected include thalamus, caudate nucleus and brainstem. They can also present as 507 
normal finding in early neuroimaging.  508 
Figure 2. The sites of infection of granulomatous amoebic encephalitis due to 509 
Balamuthia mandrillaris. The involvement of temporal lobe is observed in most cases, 510 
followed by frontal, parietal, and occipital lobe. In extracortical sites, thalamus was most 511 
affected, followed by cortico-medullary junction, cerebellum and basal ganglia.  512 
Figure 3. The sites of infection of primary amoebic meningoencephalitis due to 513 
Naegleria fowleri. The majority of cases involved the frontal lobe, followed by parietal lobe, 514 






































Table 1. The use various methods in the diagnosis of granulomatous amoebic encephalitis 
(GAE) due to Acanthamoeba spp., and Balamuthia mandrillaris and primary amoebic 
meningoencephalitis due to Naegleria fowleri. The data is presented as percent of cases 
reviewed in this study. Percentage of cases by diagnostic modalities corresponds with number 
of cases as indicated in parenthesis. Notably, some cases may involve more than one 
diagnostic modalities. 




Method Percentage of 
cases [no. of 
cases] 
GAE due to 
Acanthamoeba spp. (n=46) 
Brain biopsy Microscopy 15.21 [7] 
  PCR 4.34 [2] 
  IFA 6.52 [3] 
  Culture 4.34 [2] 
 CSF Microscopy 17.39 [8] 
  Culture 23.9 [11] 
  PCR 4.34 [2] 
 Post-mortem Microscopy 13.04 [6] 
  IFA 21.7 [10] 
  PCR 6.52 [3] 
 Skin biopsy 2.17 [1] 
GAE due to B. 
mandrillaris (n=29) 
Brain biopsy Microscopy 20.68 [6] 
  PCR 10.34 [3] 
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  IFA 13.79 [4] 
 CSF PCR 3.44 [1] 
 Post-mortem Microscopy 10.34 [3] 
  IFA 20.68 [6] 
 Skin biopsy 6.9 [8%] 
PAM due to N. fowleri 
(n=11) 
Post-mortem Microscopy 36.4 [4] 
  IFA 18.2 [2] 
  PCR 9.1 [1] 
 CSF Microscopy 18.2 [2] 











Table 2. The use various individual drugs in the treatment of granulomatous amoebic 
encephalitis (GAE) due to Acanthamoeba spp., and Balamuthia mandrillaris and primary 
amoebic meningoencephalitis due to Naegleria fowleri. Non-specific treatment includes 
general measures to reduce intracranial pressure and inflammation (mannitol, decompressive 
craniotomy, corticosteroids) and treatment for differential diagnosis (cephalosporins for 
bacterial meningitis). In cases of combinations of drugs, the therapeutic agents are calculated 
independently. The data is presented as percent of cases [no. of cases]. 
 GAE due to 
Acanthamoeba  (total 
cases reviewed = 46) 
GAE due to B. 
mandrillaris (total cases 
reviewed = 29) 
PAM due to N. 
fowleri (total cases 
reviewed = 11) 
Non-specific 19.5 [9] 20.7 [6] 18.2 [2] 
Miltefosine 15.2 [7] 13.8 [4] - 
Pentamidine 13 [6] 31 [9] - 
Sulfadiazine 19.5 [9] 34.5 [10] 18.2 [2] 




17.4 [8] 31 [9] - 
Azoles 41.3 [19] 48.3 [14] 18.2 [2] 




34.8 [16] 3.4 [1] - 
Rifampicin 37 [17] 6.9 [2] 18.2 [2] 
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Chloramphenicol 6.5 [3] - 9.1 [1] 
Pyrimethamine 2.2 [1] 6.9 [2] 9.1 [1] 
Amphotericin B 30.4 [14] 10.3 [3]  27.3 [3] 
Glycopeptides 
(Vancomycin) 
2.2 [1] - - 











Table 3. Selected cases of ameobic meningo-encephalitis with successful prognosis.  
Patient description Causative agent Treatment 
2000: a 33 year-old man  Acanthamoeba spp. Sulfazidine, pyrimethamine 
and fluconazole with left 
homonymous hemianopia 
(visual field defects) 
2002: a 45 year-old lady Acanthamoeba spp. Rifampicin, cotrimaxazole, 
fluconazole and ceftriaxone 
for 4 weeks, followed up 1 
year for facial nerve palsy 
2006: a 10 year-old boy  Acanthamoeba spp. Ketoconazole and 
rifampicin, duration of 
therapy is unknown. 
2008: 25 year-old young 
man 
Acanthamoeba spp. Miltefosine and follow up 
for 24 months. Seronegative 
for Acanthamoeba after 
treatment but neurological 
deficits did not improve. 
2009: a 63 year-old man 
with history of contact with 
contaminated water  
Acanthamoeba spp. Amphotericin B and 
rifampicin. Patient was 
discharged after 78 days of 
hospitalization. 
2011 survival case of GAE, 
the patient was a 2 year-old 
boy with underlying acute 
lymphoblastic leukemia  
Acanthamoeba spp. Meropenem, teicoplanin, 
fosfomycin, metronidazole, 
and liposomal amphotericin 
B, resulting in symptom 
resolution. 
2012: an immunocompetent 
38 year-old man  
Acanthamoeba spp. Voriconazole and 
miltefosine, he achieved 
radiological and clinical 
relief after 6 days of 
initiation of treatment. He 
was followed up for 
refractory seizure 
complication since then 
2012: a 2 year-old boy  Acanthamoeba spp. Cotrimoxazole, rifampicin, 
ketoconazole, improvement 
after 2 days 
2014: a 30 year-old man  Acanthamoeba spp. Rifampicin, 
sulfamethoxazole and 
trimethoprim, fluconazole 
for 2 weeks, asymptomatic 
after 2 weeks of follow up 
2016: a 2 year-old boy  Acanthamoeba spp. Ceftazidime, metronidazole, 
fluconazole and rifampicin 
for 3 weeks  













2016: a 12 year-old boy  
 








2003: a 64 year-old man  Balamuthia mandrillaris Amphotericin B, 
flucytosine, fluconazole, 
sulfadiazine for 5 years, 
clarithromycin for 2 years, 
pentamidine for 18 days 
 
2003: a 5 year-old girl  Balamuthia mandrillaris Flucytosine, fluconazole for 
2 years, pentamidine for 34 
days and clarithromycin for 
2 years 
2004: a 72 year-old lady  Balamuthia mandrillaris Pentamidine, sulfadiazine, 
fluconazole, clarithromycin, 
hospitalized for 13 days  
2004: a 72 year-old man  Balamuthia mandrillaris Fluconazole, sulfadiazine, 
clarithromycin and 
pentamidine isethionate, 
duration of therapy is 
unknown 
 
2006: a 10 year-old girl  Balamuthia mandrillaris Albendazole, itraconazole, 
sulfamethoxazole and 
trimethoprim for 6 months 
 
2006: an 8 year-old boy  Balamuthia mandrillaris Albendazole and 
itraconazole for 14 months 
2010: a 21 year-old lady  Balamuthia mandrillaris Albendazole, fluconazole 
for 7.5 months and 
miltefosine for 7 months 




2010: a 27 year-old man  Balamuthia mandrillaris Sulfadiazine, azithromycin 
and miltefosine for 
unspecified duration 
2011: a 27 year-old male, 
organ recipient  




2011: an 80 year-old lady  Balamuthia mandrillaris Pentamidine, itraconazole, 
azithromycin, sulfadiazine,  
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2013: a 5 year-old girl  Balamuthia mandrillaris Flucytosine, fluconazole, 
azithromycin, pentamidine 
and sulfadiazine, changed to 
final regimen azithromycin, 
fluconazole and miltefosine 
2013: 4 year-old 
immunocompetent girl with 
history of water contact with 
floods around her residence 
Balamuthia mandrillaris flucytosine, fluconazole, 
azithromycin, pentamidine 
and sulfadiazine 
2002: a 26 year-old female  Naegleria fowleri Rifampicin, amphotericin B 
and ornidazole for 2 weeks 
2008: an 8 months old male  Naegleria fowleri Amphotericin B, 
chloramphenicol and 
rifampicin and achieved 
afebrile at day 7 of treatment 
 
2013: two survivors, a 12-
year-old female and a male 
Naegleria fowleri Both were given 
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